Dr. Landgren on Daratumumab Triplet in Relapsed Myeloma

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the daratumumab (Darzalex) triplets in the treatment of patients with relapsed multiple myeloma.

In trials with 2-drug combinations versus 3-drug combination, the latter has shown more substantial results in relapsed myeloma, says Landgren.

Daratumumab was recently approved to be used in combination with bortezomib (Velcade) plus dexamethasone, or lenalidomide (Revlimid) plus dexamethasone as treatment for patients with multiple myeloma who have had at least 1 prior therapy—which is ideal for patients with relapsed myeloma who have had anywhere from 1 to 3 prior therapies.

According to Landgren, these combinations with daratumumab are going to change the landscape for the treatment of relapsed myeloma.